Tampa biotech raises $10M, eyes much bigger funding round


Intezyne Technologies Inc. says it is on solid footing after closing an oversubscribed $10 million capital offering.

The Tampa biopharmaceutical company plans to use the funding to advance two potential cancer treatments through clinical trials, said Kevin Sill, CEO. Intezyne’s two drugs in development are IT-139, to treat pancreatic, gastric and some types of melanoma, lung cancer and thyroid cancer, and IT-141, to treat colorectal and breast cancers.